Sun Pharma Advanced Research Company (SPARC) has decided to consolidate its R&D infrastructure and laboratories from multiple sites in Mumbai and Baroda to two sites in Vadodara.

This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations, enhancing operational efficiencies and reducing cycle times.

The R&D operations being conducted at Mahakali site in Mumbai and Makarpura site in Vadodara will be integrated into the company's Savli and Tandalja sites in Vadodara.

As part of the overall cost optimization effort, the Company will outsource some of the R&D activities to third party partners on an as needed basis. The consolidation of laboratory operations and the increased outsourcing could result in excess capacity in certain functions, which the company aims to streamline by the end of FY26.